Next Article in Journal / Special Issue
Impact of Antibiotic De-Escalation on Antibiotic Consumption, Length of Hospitalization, Mortality, and Cost: A Systematic Review and Meta-Analysis
Previous Article in Journal
Depression Events Associated with Proton-Pump Inhibitors in Postmarketing Drug Surveillance Data
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Brief Report

Detectable Vancomycin Stool Concentrations in Hospitalized Patients with Diarrhea Given Intravenous Vancomycin

Department of Pharmacy Practice and Translational Research, College of Pharmacy, University of Houston, Houston, TX 77204, USA
*
Author to whom correspondence should be addressed.
Pharmacoepidemiology 2023, 2(4), 283-288; https://doi.org/10.3390/pharma2040024
Submission received: 19 August 2023 / Revised: 25 September 2023 / Accepted: 27 September 2023 / Published: 28 September 2023
(This article belongs to the Special Issue Anti-Infectives: Pharmacoepidemiology and Clinical Pharmacology)

Abstract

Vancomycin is not appreciably passaged via the colonic membrane to the gastrointestinal (GI) tract in persons with an intact gut epithelium due to its large chemical structure. However; hospitalized patients with diarrhea often have a disrupted GI tract. The aim of this study was to determine the frequency of detectable vancomycin concentrations in the stool of patients with antibiotic-associated diarrhea receiving IV vancomycin. This was a multicenter cohort study of hospitalized patients with stool samples collected for Clostridioides difficile testing. Leftover stool samples were collected from patients who had received at least 3 days of IV vancomycin. Fecal vancomycin was quantified by high-performance liquid chromatography. The study cohort included 33 unique patients, majority female (54.5%) aged 60 years (range 23–84). Eighteen of thirty-three patients (54.5%) tested positive for C. difficile toxins. The average duration of systemic vancomycin administration prior to stool collection was 3.5 (range 2–15) days. Three of 33 (9%) stool samples had a detectable vancomycin concentration (range 1.2–13.2 mcg/mL). These concentrations may promote the development of vancomycin-resistant Enterococcus or van mutations in C. difficile, leading to vancomycin resistance. Further studies on implications are warranted.
Keywords: glycopeptides; stool; pharmacokinetics; Clostridioides difficile; microbiome glycopeptides; stool; pharmacokinetics; Clostridioides difficile; microbiome

Share and Cite

MDPI and ACS Style

Eubank, T.A.; Hu, C.; Gonzales-Luna, A.J.; Garey, K.W. Detectable Vancomycin Stool Concentrations in Hospitalized Patients with Diarrhea Given Intravenous Vancomycin. Pharmacoepidemiology 2023, 2, 283-288. https://doi.org/10.3390/pharma2040024

AMA Style

Eubank TA, Hu C, Gonzales-Luna AJ, Garey KW. Detectable Vancomycin Stool Concentrations in Hospitalized Patients with Diarrhea Given Intravenous Vancomycin. Pharmacoepidemiology. 2023; 2(4):283-288. https://doi.org/10.3390/pharma2040024

Chicago/Turabian Style

Eubank, Taryn A., Chenlin Hu, Anne J. Gonzales-Luna, and Kevin W. Garey. 2023. "Detectable Vancomycin Stool Concentrations in Hospitalized Patients with Diarrhea Given Intravenous Vancomycin" Pharmacoepidemiology 2, no. 4: 283-288. https://doi.org/10.3390/pharma2040024

APA Style

Eubank, T. A., Hu, C., Gonzales-Luna, A. J., & Garey, K. W. (2023). Detectable Vancomycin Stool Concentrations in Hospitalized Patients with Diarrhea Given Intravenous Vancomycin. Pharmacoepidemiology, 2(4), 283-288. https://doi.org/10.3390/pharma2040024

Article Metrics

Back to TopTop